#### Alan D T Barrett

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8971963/alan-d-t-barrett-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

183<br/>papers7,305<br/>citations48<br/>h-index79<br/>g-index200<br/>ext. papers8,274<br/>ext. citations7.6<br/>avg, IF6.28<br/>L-index

#	Paper	IF	Citations
183	Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development <i>Npj Vaccines</i> , <b>2022</b> , 7, 38	9.5	1
182	Impact of yellow fever virus envelope protein on wild-type and vaccine epitopes and tissue tropism <i>Npj Vaccines</i> , <b>2022</b> , 7, 39	9.5	1
181	Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies. <i>Npj Vaccines</i> , <b>2021</b> , 6, 139	9.5	O
180	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. <i>PLoS ONE</i> , <b>2021</b> , 16, e0253487	3.7	31
179	Flavivirus NS1 and Its Potential in Vaccine Development. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	10
178	Yellow Fever Virus (Flaviviridae) <b>2021</b> , 891-898		
177	A genetically stable Zika virus vaccine candidate protects mice against virus infection and vertical transmission. <i>Npj Vaccines</i> , <b>2021</b> , 6, 27	9.5	2
176	Japanese encephalitis virus live attenuated vaccine strains display altered immunogenicity, virulence and genetic diversity. <i>Npj Vaccines</i> , <b>2021</b> , 6, 112	9.5	2
175	Peli1 signaling blockade attenuates congenital zika syndrome. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008538	7.6	6
174	Finding Their Type: Elusive Antigenic Sites on Dengue Virus 3 Mapped with Human Antibodies. <i>Cell Host and Microbe</i> , <b>2020</b> , 27, 681-682	23.4	
173	Recent Expansion of Mosquito-Borne Pathogens Into Texas <b>2020</b> , 339-358		
172	Structure-Function of the Yellow Fever Virus Envelope Protein: Analysis of Antibody Epitopes. <i>Viral Immunology</i> , <b>2020</b> , 33, 12-21	1.7	5
171	Yellow Fever Vaccine: The Conundrum of 2 Doses, One Dose, or One-Fifth Dose to Induce and Maintain Protective Immunity. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 221, 1922-1924	7	6
170	Molecular Characterization of Hamster-Adapted Yellow Fever Virus. <i>Vector-Borne and Zoonotic Diseases</i> , <b>2020</b> , 20, 222-227	2.4	0
169	Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection. <i>Npj Vaccines</i> , <b>2020</b> , 5, 54	9.5	17
168	Zika vaccine pre-clinical and clinical data review with perspectives on the future development. <i>Human Vaccines and Immunotherapeutics</i> , <b>2020</b> , 16, 2524-2536	4.4	2
167	Baseline mapping of severe fever with thrombocytopenia syndrome virology, epidemiology and vaccine research and development. <i>Npj Vaccines</i> , <b>2020</b> , 5, 111	9.5	9

## (2018-2020)

166	Using Next Generation Sequencing to Study the Genetic Diversity of Candidate Live Attenuated Zika Vaccines. <i>Vaccines</i> , <b>2020</b> , 8,	5.3	2
165	Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex. <i>MBio</i> , <b>2019</b> , 10,	7.8	11
164	Twenty Years of Progress Toward West Nile Virus Vaccine Development. Viruses, 2019, 11,	6.2	30
163	Attenuation of Zika Virus by Passage in Human HeLa Cells. <i>Vaccines</i> , <b>2019</b> , 7,	5.3	7
162	Genotypic and phenotypic characterization of West Nile virus NS5 methyltransferase mutants. <i>Vaccine</i> , <b>2019</b> , 37, 7155-7164	4.1	5
161	Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. <i>MMWR Recommendations and Reports</i> , <b>2019</b> , 68, 1-33	37.3	29
160	Long-Term Protection After Fractional-Dose Yellow Fever Vaccination. <i>Annals of Internal Medicine</i> , <b>2019</b> , 171, 145-146	8	2
159	An attenuated Zika virus NS4B protein mutant is a potent inducer of antiviral immune responses. <i>Npj Vaccines</i> , <b>2019</b> , 4, 48	9.5	7
158	Japanese encephalitis vaccine-specific envelope protein E138K mutation does not attenuate virulence of West Nile virus. <i>Npj Vaccines</i> , <b>2019</b> , 4, 50	9.5	3
157	Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. <i>Lancet Infectious Diseases, The</i> , <b>2019</b> , 19, e31-e38	25.5	76
156	Spectrum of activity testing for therapeutics against all four dengue virus serotypes in AG129 mouse models: Proof-of-concept studies with the adenosine nucleoside inhibitor NITD-008. <i>Antiviral Research</i> , <b>2018</b> , 154, 104-109	10.8	10
155	Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development. <i>Current Opinion in Virology</i> , <b>2018</b> , 29, 72-78	7.5	21
154	Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. <i>Npj Vaccines</i> , <b>2018</b> , 3, 11	9.5	47
153	Characterization of a murine model of non-lethal, symptomatic dengue virus infection. <i>Scientific Reports</i> , <b>2018</b> , 8, 4900	4.9	21
152	Tau oligomers mediate Esynuclein toxicity and can be targeted by immunotherapy. <i>Molecular Neurodegeneration</i> , <b>2018</b> , 13, 13	19	43
151	The reemergence of yellow fever. <i>Science</i> , <b>2018</b> , 361, 847-848	33.3	38
150	Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation. <i>Npj Vaccines</i> , <b>2018</b> , 3, 24	9.5	60
149	Yellow Fever Vaccines <b>2018</b> , 1181-1265.e20		7

148	West Nile in Europe: an increasing public health problem. Journal of Travel Medicine, 2018, 25,	12.9	29
147	Structural and Nonstructural Genes Contribute to the Genetic Diversity of RNA Viruses. <i>MBio</i> , <b>2018</b> , 9,	7.8	17
146	Analysis By Deep Sequencing of Discontinued Neurotropic Yellow Fever Vaccine Strains. <i>Scientific Reports</i> , <b>2018</b> , 8, 13408	4.9	13
145	Developing Zika vaccines: the lessons for disease X. <i>Genome Medicine</i> , <b>2018</b> , 10, 47	14.4	5
144	Virulence determinants of West Nile virus: how can these be used for vaccine design?. <i>Future Virology</i> , <b>2017</b> , 12, 283-295	2.4	8
143	Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease. <i>Vaccine</i> , <b>2017</b> , 35, 5951-5955	4.1	47
142	Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day. <i>Current Infectious Disease Reports</i> , <b>2017</b> , 19, 14	3.9	62
141	Genomic Characterization of Crimean-Congo Hemorrhagic Fever Virus in Hyalomma Tick from Spain, 2014. <i>Vector-Borne and Zoonotic Diseases</i> , <b>2017</b> , 17, 714-719	2.4	18
140	A DENV-2-type-specific monoclonal antibody binds to the DENV-complex-reactive antigenic site on envelope protein domain 3. <i>Journal of General Virology</i> , <b>2017</b> , 98, 1299-1304	4.9	2
139	A lethal model of disseminated dengue virus type 1 infection in AG129 mice. <i>Journal of General Virology</i> , <b>2017</b> , 98, 2507-2519	4.9	17
138	Transstadial Transmission and Long-term Association of Crimean-Congo Hemorrhagic Fever Virus in Ticks Shapes Genome Plasticity. <i>Scientific Reports</i> , <b>2016</b> , 6, 35819	4.9	25
137	Yellow Fever in Angola and BeyondThe Problem of Vaccine Supply and Demand. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 301-3	59.2	67
136	Invasion Dynamics of Teratogenic Infections in Light of Rubella Control: Implications for Zika Virus. <i>PLOS Currents</i> , <b>2016</b> , 8,		5
135	Differential Infectivities among Different Japanese Encephalitis Virus Genotypes in Culex quinquefasciatus Mosquitoes. <i>PLoS Neglected Tropical Diseases</i> , <b>2016</b> , 10, e0005038	4.8	27
134	O5-06-05: Altering The Trajectory of Synucleinopathies by Targeting Downstream Toxicity of TAU Oligomers <b>2016</b> , 12, P391-P392		
133	Fast-Track Zika Vaccine Development - Is It Possible?. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1212	<b>?-6</b> 9.2	42
132	Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer <b>B</b> disease mouse model. <i>Journal of Neuroscience</i> , <b>2015</b> , 35, 4857-68	6.6	99
131	Current status and future prospects of yellow fever vaccines. <i>Expert Review of Vaccines</i> , <b>2015</b> , 14, 1479	-95/2	43

130	Mouse models of dengue virus infection for vaccine testing. <i>Vaccine</i> , <b>2015</b> , 33, 7051-60	4.1	38
129	A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease. <i>Journal of Virology</i> , <b>2015</b> , 89, 1254-66	6.6	59
128	Functional analysis of dengue virus (DENV) type 2 envelope protein domain 3 type-specific and DENV complex-reactive critical epitope residues. <i>Journal of General Virology</i> , <b>2015</b> , 96, 288-293	4.9	13
127	Attenuated West Nile virus mutant NS1130-132QQA/175A/207A exhibits virus-induced ultrastructural changes and accumulation of protein in the endoplasmic reticulum. <i>Journal of Virology</i> , <b>2015</b> , 89, 1474-8	6.6	10
126	A Dengue Virus Type 4 Model of Disseminated Lethal Infection in AG129 Mice. <i>PLoS ONE</i> , <b>2015</b> , 10, e012	2 <b>5.4</b> 76	36
125	Characterization of lethal dengue virus type 4 (DENV-4) TVP-376 infection in mice lacking both IFN-II in I	4.9	20
124	Assessing the need for and acceptability of a free-of-charge postpartum HPV vaccination program. <i>American Journal of Obstetrics and Gynecology</i> , <b>2014</b> , 210, 213.e1-7	6.4	8
123	Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice. <i>Vaccine</i> , <b>2014</b> , 32, 6537-43	4.1	21
122	Thermodynamic mechanism for the evasion of antibody neutralization in flaviviruses. <i>Journal of the American Chemical Society</i> , <b>2014</b> , 136, 10315-24	16.4	7
121	Understanding and Measuring the Dynamics of Infectious Disease Transmission <b>2014</b> , 304-318		
120	Veterinary Vaccines: Regulations and Impact on Emerging Infectious Diseases <b>2014</b> , 232-242		
119	Clinical Evaluation of Vaccines <b>2014</b> , 260-272		
118	Veterinary Vaccines <b>2014</b> , 181-191		
117	Development of Vaccines for Microbial Diseases <b>2014</b> , 192-211		
116	The regulatory Path to Vaccine Licensure <b>2014</b> , 212-231		1
115	Discovery and the Basic Science Phase of Vaccine Development <b>2014</b> , 109-126		
114	Microbial-Based and Material-Based Vaccine Delivery Systems <b>2014</b> , 127-151		
113	The co-stimulatory effects of MyD88-dependent Toll-like receptor signaling on activation of murine <b>I</b> cells. <i>PLoS ONE</i> , <b>2014</b> , 9, e108156	3.7	16

Control and Eradication of Human and Animal Diseases by Vaccination **2014**, 43-58

111	Pathogenesis of Infectious Diseases and Mechanisms of Immunity <b>2014</b> , 59-72		Ο
110	The History of Vaccine Development and the Diseases Vaccines Prevent <b>2014</b> , 1-32		
109	The Host Immune Response, Protective Immunity, and Correlates of Protection <b>2014</b> , 73-92		
108	Adjuvants: Making Vaccines Immunogenic <b>2014</b> , 93-108		2
107	The vaccine Development Pathway <b>2014</b> , 33-42		1
106	Political, Ethical, Social, and Psychological Aspects of Vaccinology <b>2014</b> , 335-357		2
105	Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 209, 334-44	7	54
104	Evidence for co-evolution of West Nile Virus and house sparrows in North America. <i>PLoS Neglected Tropical Diseases</i> , <b>2014</b> , 8, e3262	4.8	30
103	Vaccine Recommendations and Special Populations <b>2014</b> , 273-286		
102	Flavivirus Infections in Humans <b>2013</b> ,		1
101	Dynamic transmission of West Nile virus across the United States-Mexican border. <i>Virology</i> , <b>2013</b> , 436, 75-80	3.6	14
100	Yellow fever vaccine <b>2013</b> , 870-968		33
99	Molecular evolution of lineage 2 West Nile virus. <i>Journal of General Virology</i> , <b>2013</b> , 94, 318-325	4.9	50
98	Characterization of Epstein-Barr virus reactivation in a modeled spaceflight system. <i>Journal of Cellular Biochemistry</i> , <b>2013</b> , 114, 616-24	4.7	10
97	A West Nile virus NS4B-P38G mutant strain induces adaptive immunity via TLR7-MyD88-dependent and independent signaling pathways. <i>Vaccine</i> , <b>2013</b> , 31, 4143-51	4.1	13
96	Vertebrate attenuated West Nile virus mutants have differing effects on vector competence in Culex tarsalis mosquitoes. <i>Journal of General Virology</i> , <b>2013</b> , 94, 1069-1072	4.9	7
95	A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2013</b> , 88, 172-7	3.2	19

## (2010-2013)

94	Phylogeography of Japanese encephalitis virus: genotype is associated with climate. <i>PLoS Neglected Tropical Diseases</i> , <b>2013</b> , 7, e2411	4.8	73
93	Genetic diversity of Japanese encephalitis virus isolates obtained from the Indonesian archipelago between 1974 and 1987. <i>Vector-Borne and Zoonotic Diseases</i> , <b>2013</b> , 13, 479-88	2.4	31
92	Continued evolution of West Nile virus, Houston, Texas, USA, 2002-2012. <i>Emerging Infectious Diseases</i> , <b>2013</b> , 19, 1418-27	10.2	32
91	Molecular epidemiology and evolution of West Nile virus in North America. <i>International Journal of Environmental Research and Public Health</i> , <b>2013</b> , 10, 5111-29	4.6	39
90	Phylogeographic reconstruction of African yellow fever virus isolates indicates recent simultaneous dispersal into east and west Africa. <i>PLoS Neglected Tropical Diseases</i> , <b>2013</b> , 7, e1910	4.8	20
89	Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes. <i>Virology</i> , <b>2012</b> , 422, 386-92	3.6	11
88	Mutational analysis of the West Nile virus NS4B protein. Virology, 2012, 426, 22-33	3.6	40
87	O4-06-01: Specific clearance of tau oligomers by passive immunization <b>2012</b> , 8, P624-P625		
86	Multiple amino acid changes at the first glycosylation motif in NS1 protein of West Nile virus are necessary for complete attenuation for mouse neuroinvasiveness. <i>Vaccine</i> , <b>2011</b> , 29, 9702-10	4.1	34
85	Flavivirus-induced antibody cross-reactivity. <i>Journal of General Virology</i> , <b>2011</b> , 92, 2821-2829	4.9	163
84	Evolution of new genotype of West Nile virus in North America. <i>Emerging Infectious Diseases</i> , <b>2011</b> , 17, 785-93	10.2	64
83	Phylogeography of West Nile virus: from the cradle of evolution in Africa to Eurasia, Australia, and the Americas. <i>Journal of Virology</i> , <b>2011</b> , 85, 2964-74	6.6	174
82	Reduced avian virulence and viremia of West Nile virus isolates from Mexico and Texas. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2011</b> , 85, 758-67	3.2	25
81	Envelope and pre-membrane protein structural amino acid mutations mediate diminished avian growth and virulence of a Mexican West Nile virus isolate. <i>Journal of General Virology</i> , <b>2011</b> , 92, 2810-2	.8 <del>2</del> 0	16
80	New vaccine development for chronic brain disease. <i>Neuropsychopharmacology</i> , <b>2010</b> , 35, 354	8.7	4
79	Comparative pathogenesis and systems biology for biodefense virus vaccine development. <i>Journal of Biomedicine and Biotechnology</i> , <b>2010</b> , 2010, 236528		8
78	Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. <i>Vaccine</i> , <b>2010</b> , 28, 1075-83	4.1	59
77	Multiple pathways to the attenuation of West Nile virus in south-east Texas in 2003. <i>Virology</i> , <b>2010</b> , 405, 8-14	3.6	13

76	Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. <i>Virology</i> , <b>2010</b> , 407, 237-46	3.6	34
75	Flaviviruses (Yellow Fever, Dengue, Dengue Hemorrhagic Fever, Japanese Encephalitis, West Nile Encephalitis, St. Louis Encephalitis, Tick-Borne Encephalitis) <b>2010</b> , 2133-2156		6
74	Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. <i>Virology</i> , <b>2009</b> , 384, 16-20	3.6	43
73	Structure of yellow fever virus envelope protein domain III. Virology, 2009, 394, 12-8	3.6	30
72	Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?. <i>Current Opinion in Immunology</i> , <b>2009</b> , 21, 308-13	7.8	130
71	Development pathway for biodefense vaccines. <i>Vaccine</i> , <b>2009</b> , 27 Suppl 4, D2-7	4.1	8
70	Virulence of West Nile Virus in Different Animal Hosts <b>2009</b> , 137-153		2
69	International laboratory network for yellow fever vaccine-associated adverse events. <i>Vaccine</i> , <b>2008</b> , 26, 5441-2	4.1	3
68	Long range communication in the envelope protein domain III and its effect on the resistance of West Nile virus to antibody-mediated neutralization. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 613-622	5.4	15
67	Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses. <i>Viral Immunology</i> , <b>2008</b> , 21, 123-32	1.7	246
66	Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. <i>Journal of Virology</i> , <b>2008</b> , 82, 8828-37	6.6	127
65	The Infectious Agent. <i>Tropical Medicine</i> , <b>2008</b> , 29-73		4
64	The enigma of yellow fever in East Africa. <i>Reviews in Medical Virology</i> , <b>2008</b> , 18, 331-46	11.7	65
63	Short report: comparison of oral infectious dose of West Nile virus isolates representing three distinct genotypes in Culex quinquefasciatus. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2008</b> , 79, 951-4	3.2	14
62	Comparison of Oral Infectious Dose of West Nile Virus Isolates Representing Three Distinct Genotypes in Culex quinquefasciatus. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2008</b> , 79, 951-	9334	17
61	Genetic variation of St. Louis encephalitis virus. <i>Journal of General Virology</i> , <b>2008</b> , 89, 1901-1910	4.9	26
60	Yellow fever: a disease that has yet to be conquered. <i>Annual Review of Entomology</i> , <b>2007</b> , 52, 209-29	21.8	250
59	Vector- and Rodent-borne Diseases in Europe and North America: Distribution, Public Health Burden and Control. <i>Emerging Infectious Diseases</i> , <b>2007</b> , 13, 1278-1278	10.2	78

#### (2004-2007)

58	Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. <i>Virology</i> , <b>2007</b> , 366, 349-60	3.6	151
57	Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infections. <i>Journal of General Virology</i> , <b>2007</b> , 88, 981-990	4.9	29
56	Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. <i>PLoS Pathogens</i> , <b>2007</b> , 3, e75	7.6	190
55	A combination of naturally occurring mutations in North American West Nile virus nonstructural protein genes and in the 3Runtranslated region alters virus phenotype. <i>Journal of Virology</i> , <b>2007</b> , 81, 6111-6	6.6	29
54	A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice. <i>Virology</i> , <b>2006</b> , 349, 245-53	3.6	86
53	A mutation in the envelope protein fusion loop attenuates mouse neuroinvasiveness of the NY99 strain of West Nile virus. <i>Virology</i> , <b>2006</b> , 353, 35-40	3.6	36
52	Gamma delta T cells facilitate adaptive immunity against West Nile virus infection in mice. <i>Journal of Immunology</i> , <b>2006</b> , 177, 1825-32	5.3	67
51	Genome analysis and phylogenetic relationships between east, central and west African isolates of Yellow fever virus. <i>Journal of General Virology</i> , <b>2006</b> , 87, 895-907	4.9	24
50	Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. <i>Vaccine</i> , <b>2006</b> , 24, 2803-9	4.1	31
49	Introductions of West Nile virus strains to Mexico. <i>Emerging Infectious Diseases</i> , <b>2006</b> , 12, 314-8	10.2	58
48	Phenotypic and molecular characterization of a non-lethal, hamster-viscerotropic strain of yellow fever virus. <i>Virus Research</i> , <b>2005</b> , 110, 65-71	6.4	9
47	Phylogenetic analysis of North American West Nile virus isolates, 2001-2004: evidence for the emergence of a dominant genotype. <i>Virology</i> , <b>2005</b> , 342, 252-65	3.6	195
46	West Nile Virus isolation in human and mosquitoes, Mexico. Emerging Infectious Diseases, 2005, 11, 144	91522	47
45	Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. <i>Journal of Virology</i> , <b>2005</b> , 79, 8339-47	6.6	250
44	West Nile Virus Isolation in Human and Mosquitoes, Mexico. Emerging Infectious Diseases, 2005, 12, 144	9111452	2
43	Genome sequence and attenuating mutations in West Nile virus isolate from Mexico. <i>Emerging Infectious Diseases</i> , <b>2004</b> , 10, 2221-4	10.2	62
42	Genetic divergence and dispersal of yellow fever virus, Brazil. <i>Emerging Infectious Diseases</i> , <b>2004</b> , 10, 1578-84	10.2	75
41	Current status of the Arilvax; yellow fever vaccine. Expert Review of Vaccines, 2004, 3, 413-20	5.2	5

40	Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 189, 669-76	7	61
39	Use of a recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile virus infection. <i>Journal of Clinical Microbiology</i> , <b>2004</b> , 42, 2759-65	9.7	54
38	Molecular determinants of antigenicity of two subtypes of the tick-borne flavivirus Omsk haemorrhagic fever virus. <i>Journal of General Virology</i> , <b>2004</b> , 85, 1619-1624	4.9	17
37	Characterization of a West Nile virus isolate from a human on the Gulf Coast of Texas. <i>Journal of Clinical Microbiology</i> , <b>2004</b> , 42, 5375-7	9.7	13
36	Emergence of attenuated West Nile virus variants in Texas, 2003. Virology, 2004, 330, 342-50	3.6	83
35	1H, 13C and 15N resonance assignments for domain III of the West Nile virus envelope protein. <i>Journal of Biomolecular NMR</i> , <b>2004</b> , 29, 445-6	3	2
34	Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. <i>Vaccine</i> , <b>2004</b> , 22, 3722-6	4.1	61
33	West Nile virus: where are we now?. Lancet Infectious Diseases, The, <b>2004</b> , 4, 547-56	25.5	187
32	Genetic variation among temporally and geographically distinct West Nile virus isolates, United States, 2001, 2002. <i>Emerging Infectious Diseases</i> , <b>2003</b> , 9, 1423-9	10.2	53
31	West Nile virus in Mexico: evidence of widespread circulation since July 2002. <i>Emerging Infectious Diseases</i> , <b>2003</b> , 9, 1604-7	10.2	120
30	Limited evolution of West Nile virus has occurred during its southwesterly spread in the United States. <i>Virology</i> , <b>2003</b> , 309, 190-5	3.6	99
29	Natural and nosocomial infection in a patient with West Nile encephalitis and extrapyramidal movement disorders. <i>Clinical Infectious Diseases</i> , <b>2003</b> , 36, E140-5	11.6	36
28	Molecular characterization of a hamster viscerotropic strain of yellow fever virus. <i>Journal of Virology</i> , <b>2003</b> , 77, 1462-8	6.6	39
27	Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. <i>Virology</i> , <b>2002</b> , 296, 17-23	3.6	209
26	Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. <i>Journal of Virology</i> , <b>2002</b> , 76, 13097-100	6.6	215
25	Arilvax (PowderJect). Current Opinion in Investigational Drugs, <b>2002</b> , 3, 992-5		1
24	Current status of flavivirus vaccines. Annals of the New York Academy of Sciences, 2001, 951, 262-71	6.5	54
23	West Nile virus strains differ in mouse neurovirulence and binding to mouse or human brain membrane receptor preparations. <i>Annals of the New York Academy of Sciences</i> , <b>2001</b> , 951, 332-5	6.5	25

22	Genetic variation in the 3Rnon-coding region of dengue viruses. Virology, 2001, 281, 75-87	3.6	100
21	Amino acid substitution(s) in the stem-anchor region of langat virus envelope protein attenuates mouse neurovirulence. <i>Virology</i> , <b>2001</b> , 286, 54-61	3.6	14
20	Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. <i>Journal of Virology</i> , <b>2001</b> , 75, 6999-7008	6.6	85
19	Diagnosis of Oropouche virus infection using a recombinant nucleocapsid protein-based enzyme immunoassay. <i>Journal of Clinical Microbiology</i> , <b>2001</b> , 39, 2445-52	9.7	9
18	Langat virus M protein is structurally homologous to prM. <i>Journal of Virology</i> , <b>2001</b> , 75, 3999-4001	6.6	4
17	Phylogeny of the Simbu serogroup of the genus Bunyavirus. <i>Journal of General Virology</i> , <b>2001</b> , 82, 2173	-241&1	68
16	Jatobal virus is a reassortant containing the small RNA of Oropouche virus. Virus Research, 2001, 77, 25	-3604	49
15	Nucleotide sequences and phylogeny of the nucleocapsid gene of Oropouche virus. <i>Journal of General Virology</i> , <b>2000</b> , 81, 743-8	4.9	53
14	Interaction of yellow fever virus French neurotropic vaccine strain with monkey brain: characterization of monkey brain membrane receptor escape variants. <i>Journal of Virology</i> , <b>2000</b> , 74, 290	03-6	27
13	The French neurotropic vaccine strain of yellow fever virus accumulates mutations slowly during passage in cell culture. <i>Virus Research</i> , <b>2000</b> , 69, 31-9	6.4	12
12	Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. <i>Journal of Virology</i> , <b>2000</b> , 74, 3227-34	6.6	282
11	Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. <i>Virology</i> , <b>1999</b> , 261, 309-18	3.6	32
10	Attenuation of Japanese encephalitis virus by selection of its mouse brain membrane receptor preparation escape variants. <i>Virology</i> , <b>1998</b> , 241, 30-6	3.6	61
9	Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. <i>Virology</i> , <b>1998</b> , 244, 59-65	3.6	47
8	Detection and quantification of Epstein-Barr virus EBER1 in EBV-infected cells by fluorescent in situ hybridization and flow cytometry. <i>Journal of Virological Methods</i> , <b>1998</b> , 75, 83-91	2.6	11
7	Yellow fever 17D vaccine virus isolated from healthy vaccinees accumulates very few mutations. <i>Virus Research</i> , <b>1998</b> , 55, 93-9	6.4	30
6	Yellow fever vaccines. <i>Biologicals</i> , <b>1997</b> , 25, 17-25	1.8	70
5	Japanese encephalitis and dengue vaccines. <i>Biologicals</i> , <b>1997</b> , 25, 27-34	1.8	37

4	Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. <i>Virology</i> , <b>1997</b> , 230, 376-80	3.6	29	
3	Genetic variation in yellow fever virus: duplication in the 3Rnoncoding region of strains from Africa. <i>Virology</i> , <b>1996</b> , 225, 274-81	3.6	81	
2	Antigenic characterization of the live attenuated Japanese encephalitis vaccine virus SA14-14-2: a comparison with isolates of the virus covering a wide geographic area. <i>Vaccine</i> , <b>1992</b> , 10, 861-72	4.1	28	

Arthropod-Borne Flaviviruses1267-1311